Business Context and Reporting Period
This Form 8-K is filed by Big Rock Partners Acquisition Corp. (BRPA) on February 23, 2021. The filing discloses a previously announced Agreement and Plan of Merger between BRPA, NeuroRx, Inc. (NeuroRx), and a wholly-owned subsidiary of BRPA. Under the agreement, the subsidiary will merge with NeuroRx, making NeuroRx a wholly-owned subsidiary of BRPA. The filing also reports significant clinical trial results for NeuroRx's lead candidate, ZYESAMI (aviptadil).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either BRPA or NeuroRx. This document serves as a current report on material events rather than a periodic financial statement.
Material Changes and Clinical Developments
The primary material change reported is the announcement of interim results from NeuroRx's Phase 2b/3 trial of ZYESAMI for treating respiratory failure due to critical COVID-19. Key developments include:
- Clinical Outcome: The trial demonstrated 10-day accelerated recovery from respiratory failure in critically ill patients treated with high flow nasal oxygen at the day 28 interim endpoint.
- Regulatory Intent: NeuroRx intends to file for Emergency Use Authorization (EUA) if positive results are sustained at the day 60 endpoint, aligning with new FDA guidance.
- Collaboration: The trial was performed in collaboration with Relief Therapeutics Holdings, AG.
Guidance, Outlook, and Risks
Management commentary focuses on the potential for regulatory approval and the completion of the business combination. The filing includes extensive forward-looking statements regarding the merger and drug development.
Key Risks and Uncertainties:
- Merger Completion: Risks regarding the approval, timing, and ability to complete the proposed business combination.
- Listing Status: Uncertainty regarding BRPA's ability to remain listed on the Nasdaq Capital Market prior to and after the closing of the transaction.
- Regulatory Approval: Inherent uncertainty associated with the FDA approval process and the success of the EUA application.
- Operational Disruption: Risk that the transaction disrupts NeuroRx's current plans and operations.
- Market Factors: Potential adverse effects from economic, business, competitive factors, and the ongoing impact of the COVID-19 pandemic.
- Verify the final results of the ZYESAMI trial at the day 60 endpoint to confirm the basis for the intended EUA filing.
- Review the definitive proxy statement/prospectus filed on Form S-4 for detailed terms of the merger and financial projections.
- Confirm the status of the proposed business combination and any conditions precedent to closing.
- Monitor FDA communications regarding the Emergency Use Authorization application for aviptadil.
- Check Nasdaq listing status updates for BRPA leading up to the merger closing.
Investors are urged to read the Registration Statement on Form S-4, which includes the proxy statement and prospectus, for detailed risk factors.